|Bid||80.78 x 800|
|Ask||80.79 x 1400|
|Day's Range||79.42 - 81.94|
|52 Week Range||61.05 - 82.80|
|Beta (3Y Monthly)||1.07|
|PE Ratio (TTM)||27.50|
|Earnings Date||Jul 25, 2019|
|Forward Dividend & Yield||0.88 (1.08%)|
|1y Target Est||83.60|
Baxter manufacturers medically necessary products and the company enjoys a high market share across multiple health care segments, Mishan wrote in the note. The company deserves credit for recent new product launches and geographic expansions but these aren't notable enough to exceed management's 5% to 6% organic growth through 2023.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Baxter International Inc. New York, June 26, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Baxter International Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
President Trump's threats to ratchet up tariffs on goods from China will have a minimal impact on biotech companies, experts say. Meanwhile, medtech companies dodged tariffs in Mexico.
Generally speaking, summer is a lethargic time for the market. With investors thinking about vacations, ball games and cookouts, and in the absence of many catalysts, it's just a slow time of year. On average, the S&P 500 gains a very modest 1% between the beginning of June and the end of August, leading into what's often a rather rough September.There are always exceptions though.Granted, these exceptions are often born out of unusual circumstances, and may need the right nudge to realize their full potential. Given how lethargic the summer of 2019 is shaping up to be though, investors looking to add a little extra zip to sleepy portfolios may want to take some strategic action.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Tech Stocks to Buy Now for 2025 With that as the backdrop, here's a rundown of seven stocks to buy with the best shot at bucking the brewing stagnation and mustering a respectable summertime gain. They've already demonstrated some unusually impressive -- and new -- bullishness, but more may be in store. Whirlpool (WHR) Click to EnlargeThe ongoing tariff war -- and the ensuing economic headwind it has helped create -- has prompted investors and analysts alike to identify those names that seem the most vulnerable. In so doing, investors have largely overlooked names that are able to shrug off those woes.That's Whirlpool (NYSE:WHR) right now, says KeyBanc's Kenneth Zener. He suggests the appliance maker is actually shelter (of sorts) from the storm, positioned to capitalize on what could turn into lower mortgage rates. It's also somewhat of a beneficiary of a moderating economy; consumers may buy a dishwasher rather than purchase a new vehicle.Simultaneously, even if out of necessity, the company's cost-cutting initiatives are working. This year's EBIT margin forecast of between 6.5% and 6.8% marks a 40 basis point improvement, though the company anticipates EBIT margins of more than 10% by 2020. That should be enough to drive profit growth of more than 10% this year and next.The market has finally taken notice. After a rough 2018, WHR stock is up 40% from its late-December low, and up more than 20% since late May. Yet, the bulk of last year's loss has yet to be reclaimed. Agco (AGCO) Click to EnlargeGiven the uncertainty that has kept shares of farming equipment name Deere & Company (NYSE:DE) from moving forward for well over a year now, it would be easy to assume the same woes apply to smaller rival Agco (NYSE:AGCO). Indeed, a month ago, BofA Merrill made a point of saying that would be the case, lowering its stance on AGCO stock to "Underperform" in anticipation of falling demand.AGCO shares took a hit, unwinding a sizeable piece of this year's 36% rally. Curiously though, AGCO didn't stay down. It's almost back to May's highs, which are within sight of record highs. * 7 Top-Rated Biotech Stocks to Invest In Today That rebound likely has much to do with the fact that, rather than worrying about what may or may not happen in China, which is out of the company's control, Agco is focusing on something it can control. That's improving margins. CEO Martin Richenhagen said that plainly in a CNBC interview from last month, though recent investments in production as well as outright purchases of complementary companies also set the stage for better margins. Baxter International (BAX) Click to EnlargeMedical supply and equipment company Baxter International (NYSE:BAX) is never going to be a red-hot growth machine. But, what it lacks in explosiveness it more than makes up for in consistency.Most investors would struggle to name one specific product Baxter offers. Millions of caregivers and patients would struggle with Baxter-made wares though. From infusion systems to surgical tools to kidney dialysis solutions, it does a little of everything for a lot of people.That diversity is the key to its consistency, and while it would be untrue to suggest the company never fails to grow its business, it would also be untrue to suggest it doesn't usually drive quarterly top-line growth. That's a core reason BAX stock has been such a reliable performer. It's also a key part of the reason BAX stock was able to shrug off last year's stumble and reclaim all that was lost. Record highs are once again back in sight. Discovery Communications (DISCA) Click to EnlargeA recovery of most of the television production industry's names certainly provided a tailwind, but Discovery Communications (NASDAQ:DISCA) has emerged from that sweeping turnaround as one of the hot stocks to buy again.You know the company's flagship and namesake television channel. But, it's much more than that. Discovery is also the studio behind HGTV, Food Network, TLC, Animal Planet and the Oprah Winfrey Network … and more.It's a business seemingly with a cloudy future. The advent of all sorts of streaming options against a backdrop of cord-cutting would theoretically work against the company.But, as few have fully appreciated, Discovery is wisely working with that tide rather than against it. Namely, it's more likely to partner with the names disrupting the tradition television industry. Discovery's content is available through YouTube, for instance, and Animal Planet is a choice on most so-called skinny bundles. * 10 Monster Growth Stocks to Buy for 2019 and Beyond This willingness to rethink how to most profitably distribute content in an ever-changing market is a big part of the reason 2018 was so fruitful for DISCA stock after a rocky 2017. Revenue is projected to grow more than 5% this year, and next, accompanied by comparable profit growth. But, there's still lots of ground for DISCA to make up from years of sub-par performance. A newly developed rising support line (white, dashed) is helping to do just that. Cornerstone OnDemand (CSOD) Click to EnlargeCornerstone OnDemand (NASDAQ:CSOD) isn't a household name, though it would be a nice addition to most household's portfolios.Cornerstone OnDemand offers cloud-based human resources management software. It's not exactly riveting stuff, nor is it high growth. It's got teeth though, but more than that, the company is currently in the middle of a major pivot. This year is the one where Cornerstone finally achieves enough scale to drive a profit explosion. Last year's per-share earnings of 74 cents are expected to reach $1.04 this year, and jump 40% next year to $1.46 on sales growth that isn't nearly as impressive.Analysts agree that the business model and the recurring revenue it produces makes Cornerstone currently undervalued. The consensus target now stands at $64.11, or 14% above the stock's current price. The uptrend that's been in place since early last year, however, says CSOD stock is en route to that level. Federal Realty Investment Trust (FRT) Click to EnlargeAny new exposure to the retail landscape, particularly in the current environment, isn't easy to take on, even if the play is acting as a landlord to consumer-facing companies. Retail REIT Federal Realty Investment Trust (NYSE:FRT) isn't nearly as vulnerable as it would be easy to assume it is, however, for a couple of reasons.Chief among them is where Federal Realty Investment Trust sets up shop. Most of its properties make up an upscale destination for diners and shoppers, and aren't as impacted as a rural shopping center or less affluent areas might be by economic turbulence.The second reason FRT is taking shape as one of the best stocks to buy this summer? While the retail apocalypse may still be underway, it has become something more predictable and manageable. This REIT's feel for development and redevelopment delivers the experience and mixed-use areas consumers want; much of the retail apocalypse was self-imposed by retailers that failed to keep their finger on the pulse of the market. * 7 Top-Rated Biotech Stocks to Invest In Today It's a nuance investors largely missed a couple years back, but the 27% gain from its early 2018 low suggest they're now remembering. The recent weakness is a chance to get into the bigger-picture uptrend at a bargain price. Incyte (INCY) Click to EnlargeFinally, add Incyte (NASDAQ:INCY) to your list of stocks to buy for the coming summer months.Incyte is the name behind a drug called ruxolitinib, though it's better known by its brand name Jakafi. It has proven to be an effective treatment for a handful of blood-related diseases, including a rare cancer called myelofibrosis and a similar condition called polycythemia vera. It may be a one-trick pony, so to speak, but when that pony is Jakafi, that's ok. That one drug is expected to improve the top line by nearly 10% this year, and more than 16% next year, driving Incyte much deeper into the black.Although it has been a compelling success story, INCY stock is no stranger to volatility. Those swings, however, have proven relatively predicable. A technical floor near $60 that took shape (again) last year ultimately served as a springboard for this year's bullishness, and a former ceiling near $74 has since turned into a support level.Now on solid footing, the bulls are starting to reach for higher highs, not unlike the beginning of the big move seen in 2016.As of this writing, James Brumley did held a long position in Cornerstone On-Demand. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 5 Red-Hot IPO Stocks to Buy for the Long Run * 5 Stocks to Buy for $20 or Less * 4 Dow Jones Stocks Ready to Rise Compare Brokers The post 7 Hot Stocks to Buy for a Seemingly Sleepy Summer appeared first on InvestorPlace.
Baxter International Inc. (BAX), a global innovator in renal care, showcased 19 data presentations on therapy options at the 56th ERA-EDTA Congress, Budapest, Hungary, June 13-16. The presentations spanned the renal care continuum, from chronic kidney disease (CKD) management to peritoneal dialysis (PD) and hemodialysis (HD).
Baxter (BAX) expects its bottom line to rise in the second quarter of 2019, courtesy to Renal Care and Clinical Nutrition businesses.
Baxter (BAX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Baxter International Inc. (BAX), a global innovator in renal care, today announced receipt of a major research and development (R&D) grant from the German Federal Ministry of Education and Research (BMBF)’s “From Material to Innovation” program to lead a consortium investigating an anticoagulation-free hemodialysis (HD) option for end-stage renal disease (ESRD) patients. The grant provides €1.5 million in funding over three years to Baxter’s research team in Hechingen, Germany, and the consortium partners to find a solution that will improve health-related, quality-of-life outcomes for the millions of patients receiving HD therapy globally.
Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter. Trends reversed 180 degrees during the first quarter amid Powell's pivot and optimistic expectations towards a trade deal with China. Hedge funds and institutional investors tracked by Insider Monkey usually invest a disproportionate amount of their […]
Baxter International Inc NYSE:BAXView full report here! Summary * Perception of the company's creditworthiness is neutral * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for BAX with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BAX. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding BAX totaled $79.78 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | NeutralThe current level displays a neutral indicator. BAX credit default swap spreads are near their highest levels of the last 3 years, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Baxter International Inc. (BAX), a leading global medical products company, will host a conference call to discuss its second quarter 2019 financial results on Thursday, July 25, 2019, at 7:30 a.m. Central Time. The Conference ID is 2089733.
DEERFIELD, Ill.-- -- Enhancements designed to give healthcare providers access to more comprehensive treatment data and improve clinic workflow New study further supports value of remote patient management technology to personalize dialysis treatments, reduce alarms and in-person visits, while saving clinicians and patients significant time Baxter International Inc. , a global innovator in renal care, ...
Baxter International Inc. (NYSE:BAX), a large-cap worth US$40b, comes to mind for investors seeking a strong and...
The Baxter International Foundation, the philanthropic arm of Baxter International Inc. (BAX), announced today a $2.2 million grant to Operation Smile, one of the world’s largest volunteer-based surgical nonprofit organizations, to deliver free surgical and multidisciplinary care to underserved communities in India. During the next three years, the grant will support Operation Smile’s year-round care centers in Mumbai, Srinagar and Bangalore—operated in partnership with the Inga Health Foundation—along with a new care center in Durgapur, West Bengal.
Baxter International Inc. (BAX), a global leader in acute care therapies, announced today that the peer-reviewed journal Blood Purification published a supplemental issue sponsored by Baxter that features real-world clinical experience with the company’s Oxiris filter, which can be used simultaneously in continuous renal replacement therapy (CRRT) and in the removal of cytokines and endotoxin to aide in the management of acute kidney injury (AKI) patients with sepsis. The studies, which are being highlighted at the 37th Vicenza Course on AKI and CRRT in Italy this week, add to the body of scientific knowledge around the use of extracorporeal (outside the body) blood purification (EBP) to address critical conditions.
Baxter (BAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Synchrony Financial announced before the opening bell Thursday that it will increase its quarterly dividend by a penny, following dividend increases by Phillips 66 and Baxter International.
Baxter International Inc. (BAX), a leading global medical products company, today announced that representatives of the company will conduct a series of Fixed Income Investor Presentations on Thursday, May 9, 2019.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Many investors are still learning about the various metrics that can be useful when analysing a stock...